Incannex Healthcare Ltd (ASX:IHL, NASDAQ:IXHL)'s Mark Bleackley tells Andrew Scott about a study that investigates the neuro-protective properties of the company's cannabinoid asset IHL-216A in an animal model of sports-injury related concussion. The results of the study are positive, and Incannex is now preparing for an pre-IND (investigational new drug) meeting with the FDA to progress its plans for the asset.
Incannex Healthcare study targeting concussion reveals neuro-protective properties of treatment
